142 Chapter 4 Supplemental Table 2. Continued No dexamethasone-induced neurobehavioral problems (ΔSDQ<5) Median (IQR) or n (%) DT-P n = 34 Thermometer T1 4 (0-7) Thermometer T2 5.5 (2-7) Thermometer delta (T2-T1)4 0 (0-2) Total score 6 (1-12) Received support5 No 4 (11.8) Yes 30 (88.2) Perceived lack of understanding6 No 33 (97.1) Yes 1 (2.9) Parental chronic illness No 27 (79.4) Yes 7 (20.6) Support questionnaire n = 34 Psychological support child No 29 (85.3) Yes 5 (14.7) Psychological support parent(s)7 No 31 (91.2) Yes 3 (8.8) Social work support for parent(s) No 29 (85.3) Yes 5 (14.7) Information regarding side effects None 2 (5.9) Only behavioral 3 (8.8) Only somatic 0 Both 29 (85.3) Information sufficient8 No 4 (11.8) Yes 30 (88.2) Extra support on T29 No 31 (96.9) Yes 1 (3.1) Dexamethasone pharmacokinetics n = 31 Dexamethasone AUC mg*h/L 0.185 (0.128-0.320) Candidate SNP Bcl-1 rs41423247 n = 35 Additive model (alternate allele dosage G>C) 0.881 (0.049-0.998) Dominant risk allele CC 16 (45.7) CG+GG 19 (54.3)
RkJQdWJsaXNoZXIy MTk4NDMw